Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter February 1, 2012

Monocyte chemoattractant protein-1 and paraoxonase-1 and 3 levels in patients with sepsis treated in an intensive care unit: a preliminary report

  • Teresa Sans , Anna Rull , Jose Luna , Bharti Mackness , Michael Mackness , Jorge Joven , Marcos Ibañez , Rainer Pariente , Marta Rodriguez , Xavier Ortin , Gaspar Masdeu and Jordi Camps EMAIL logo

Abstract

Background: There is considerable interest in the research of molecules modulating the acute inflammatory response in patients with sepsis. Paraoxonases (PON) are antioxidant and anti-inflammatory enzymes that inhibit the production of the monocyte chemoattractant protein-1 (MCP-1). This preliminary study investigated changes in PON status and MCP-1 concentrations in critically ill patients with severe sepsis treated in an ICU and their relationship with the evolution of disease.

Methods: This was a longitudinal, prospective and observational study on 15 patients with sepsis, studied at baseline and on days 1, 2, 5, 7 and 10 of their stay in the ICU. In all the patients we measured serum PON1 and PON3 concentrations, PON1 paraoxonase and lactonase activities, serum MCP-1 concentrations, and several standard biochemical and haematological parameters.

Results: MCP-1 concentration significantly decreased with the resolution of sepsis, and this decrease was especially important during the first 5 days of hospitalisation. PON1 and PON3 tended to decrease during the first 5 days in ICU and significantly increased in days 7 and 10. Linear regression analysis showed significant and direct correlations among serum MCP-1 concentration and lactate levels at baseline. At the end of stay, PON1 paraoxonase and lactonase activities were significantly correlated with organ system function measurements.

Conclusions: We observed an inverse pattern between changes in MCP-1, and PON1 and PON3 levels in patients with sepsis, this was related to the resolution of their infection after receiving treatment in an ICU.


Corresponding author: Dr. Jordi Camps, Unitat de Recerca Biomèdica, Hospital Universitari de Sant Joan, C. Sant Joan s/n, 43201-Reus, Catalunya, Spain Phone: +34 977 31 03 00, Fax: +34 977 31 25 69

Received: 2011-12-2
Accepted: 2012-1-1
Published Online: 2012-02-01
Published in Print: 2012-08-01

©2012 by Walter de Gruyter Berlin Boston

Downloaded on 27.5.2024 from https://www.degruyter.com/document/doi/10.1515/cclm-2011-0896/html
Scroll to top button